Hyperpolarized Xenon-129 MRI for Idiopathic Pulmonary Fibrosis

(XeMRIIPF Trial)

Overseen by John Kim, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase < 1

Waitlist Available

Sponsor: University of Virginia

No Placebo Group

Trial Summary

What is the purpose of this trial?

Idiopathic pulmonary fibrosis has a poor prognosis with limited treatment options. The Investigator hypothesize hyperpolarized Xe129-MRI can be performed in patients with IPF and repeated over time which will detect deficiencies related to perfusion in the lung.

Research Team

John Kim, MD

Principal Investigator

University of Virginia

Eligibility Criteria

This trial is for adults diagnosed with Idiopathic Pulmonary Fibrosis who can consent to the study. It's not suitable for those with claustrophobia, metal implants, severe heart conditions, chronic kidney failure, cirrhosis, or those needing continuous oxygen. Pregnant or lactating individuals and those with recent respiratory infections are also excluded.

Inclusion Criteria

I have been diagnosed with idiopathic pulmonary fibrosis.

Able to provide informed consent

I am 18 years old or older.

Exclusion Criteria

I can follow simple instructions and remain still for 10-15 seconds.

I don't have conditions or devices that prevent MRI scans.

I have had a heart attack, stroke, or my high blood pressure is not well controlled.

Treatment Details

Interventions

• Hyperpolarized Xenon-129 (Gas)

Trial Overview The trial tests whether a type of lung imaging called Hyperpolarized Xenon-129 MRI can help detect changes in lung perfusion over time in patients with Idiopathic Pulmonary Fibrosis.

Participant Groups

Group I: IPF subjects Experimental Treatment 1 Intervention

IPF subjects will undergo Xe-129 MRI

Who Is Running the Clinical Trial?

University of Virginia

Lead Sponsor

Trials

802

Recruited

1,342,000+

James E. Ryan

University of Virginia

Chief Executive Officer since 2018

J.D. from Harvard Law School

Nikki Hastings

University of Virginia

Chief Medical Officer since 2018

Ph.D. in Biomedical Engineering from University of Virginia